Laddar Evenemang

Trends in Metabolic Studies of Pharmaceutical Drugs


Drug metabolism studies are challenging and require advanced, often multiplex, analytical chemistry techniques for their execution. These studies can be performed according to industry standards, or have bespoke designs to address specific questions in a given drug project. Studies aimed at identifying drug metabolites and/or the enzymes that catalyse their formation, as well as comparing the metabolites formed in non-clinical toxicity species to human, are essential in the drug discovery and development process, as outlined in the most relevant regulatory guidelines like ICH M3(R2), ICH M12 and Safety Testing of Drug Metabolites (FDA). This meeting will focus on drug metabolism and the analytical and biological technology advancements employed in these studies.


Register here


Target group

This meeting is for those responsible for the development of a drug (all modalities except ATMP) in small- and medium-sized companies. In particular, industry or academic scientists who are active in studying the metabolism of drugs and/or developing bioanalytical methods to be employed in metabolism studies will be interested in the content of this workshop

Time and venue

The meeting is held on Wednesday, May 22 at Apotekarsocieteten, Wallingatan 26 A in Stockholm.


Programme in PDF

Participation fee

The early participation fee is 3500 SEK excl. VAT until April 5 and after that 5000 SEK excl. VAT.

Postersession and short oral presentations

2 short lectures 15 min each will be selected from registered participants.
Interested, please send a posterabstract by the latest on April 1 to:
Please, also remember to fill in ”I will present a poster” at the registration form.

Abstract instructions

Partnership possibilities

Partnership possibilities

For questions regarding registration etc, please contact


Organizing Committée

Douglas Westerlund, Uppsala University
Mikael Hedeland, Uppsala University
Moa Andresen Bergström, Sahlgrenska University Hospital, Göteborg
Suzanne Iverson Hemberg, Toxicology Knowledge Team, Södertälje
Ulrik Jurva, AstraZeneca, Göteborg


For further questions please contact:


Register here